Intertek offers Protein structure, higher-order structure, GMP testing, PK and immunogenicity. Services should be matched to the intended study and assay requirements.
United Kingdom / United StatesFull profile →
Company database
Profiles, sources, and comparisons are open. Choose a field on the left to see its companies.
Search & refine Filters update automatically
Disease tags identify mentions in recorded facts or pipeline text, not approved indications or a complete pipeline. Platform service providers may have no disease-specific tag.
471 matching companiesShowing 24 / 471
The website explicitly offers PROTAC and molecular glue screening, including HiBiT, proteomics, ternary-complex structures, ADME/DMPK, in vivo formulations, and safety services.
United StatesFull profile →
Offers formulation and process concept design, preformulation, development, and manufacturing, with additional disclosed expertise in semisolid and ophthalmic dosage forms.
United KingdomFull profile →
Specializes in single- and multidose liquid CDMO services, including eye drops, BFS unit doses, and oral liquid stick packs. The Bordeaux development page lists formulation and analytical development for solutions, suspensions, gels, and emulsions.
FranceFull profile →
Alnylam develops RNA interference medicines and presents its delivery platforms, marketed products, clinical programs, and scientific materials on its official website. This profile identifies a drug developer, rather than a contract service provider.
United StatesFull profile →
Current disclosures include early drug product services at Longmont, including preformulation, FIH capsules and bottles, immediate-release, and enteric or extended-release products. The Mirabel/Whippany drug product businesses were sold in 2023, so their historical commercial network is excluded.
United StatesFull profile →
Ionis describes a portfolio of RNA- and DNA-targeted medicines, with separate pipeline, medicines, clinical-trial, and scientific-publication resources. Product-specific mechanisms and development status should be checked against dated disclosures.
United StatesFull profile →
Wave develops RNA-targeting medicines using RNA interference and RNA editing approaches. Its October 27, 2026 update describes WVE-007 as an investigational GalNAc-siRNA and WVE-006 as an investigational RNA-editing oligonucleotide. These are distinct modalities, not mRNA products.
United StatesFull profile →
A Canadian CRO specializing in solid-state science and crystallization engineering, including polymorph, salt, and cocrystal screening and process optimization.
CanadaFull profile →
Arrowhead develops RNAi therapeutics using its TRiM platform, which combines RNA triggers, targeting ligands, linkers, and chemical modifications. Liver and extrahepatic programs must be assessed by candidate and indication.
A Spanish solid-state and chemical R&D CRO offering screening, characterization, and scale-up of polymorphs, cocrystals, salts, and solvates.
SpainFull profile →
A solid-form screening and preclinical development CRO combining experimental screening with computational methods; MicroED is offered through its XtalPi partnership.
SpainFull profile →
Uses mSAS supercritical-fluid technology for crystal and particle engineering and enhanced polymorph screening.
United Kingdom / ChinaFull profile →
The CRO/CDMO solid-state team offers discovery, screening, crystallization development, and evaluation of new API solid forms.
ChinaFull profile →
Silence Therapeutics develops siRNA medicines through its mRNAi GOLD platform. The name refers to RNA interference and gene silencing; it should not be classified as an mRNA-expression platform.
An Ipca-owned small-molecule CDMO offering solid-state chemistry, salt and cocrystal screening, and chiral resolution support.
United KingdomFull profile →
Dyne describes its FORCE platform as a transferrin-receptor-binding Fab, linker, and therapeutic payload for muscle and CNS delivery. Oligonucleotide conjugation and candidate-specific clinical results should be assessed separately.
NIS published original research on a commercial small-molecule MicroED workflow and adopted the unified TrueCourse brand with Proteos in 2026.
United StatesFull profile →
Certara offers model-informed drug-development services and biosimulation software. Its public portfolio includes Phoenix for PK/PD analysis and Simcyp for PBPK modeling, alongside development and regulatory support. Software availability does not establish a model's fitness for a particular decision.
United StatesFull profile →
Simulations Plus offers modeling and simulation software and consulting across discovery and development. Its public software portfolio includes GastroPlus, MonolixSuite, and QSP tools. Modeling choices and validation should follow the intended scientific question.
United StatesFull profile →
The website offers commercial MicroED using cryo-TEM for structural analysis of powders, small molecules, polymorphs, and mixtures.
ChinaFull profile →
A drug discovery CRO that launched small-molecule MicroED in 2020 and expanded the platform in 2021 with explicit protein and small-molecule applications.
FranceFull profile →
The website has dedicated MicroED solid-state testing and structure analysis pages supporting pharmaceutical solid-state and crystal structure questions.
United StatesFull profile →
CDMO services cover small molecules, peptides, conjugates, and oligonucleotide therapeutics. The group also sells APIs; group financials are not equivalent to a stand-alone CDMO segment.
ChinaFull profile →
Coverage expands from sourced records; this database does not claim all biopharma companies.